

PDL

[View the current PDL Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/8122-PDL.html) (<http://www.bioportfolio.com/biocorporate/8122-PDL.html>)

Contact Details:

3955 Annapolis

Plymouth

MA

55447

United States of America

Tel: 612 551 6735

Fax:

Email:

Recent Publications by PDL:



- [Impact of oxygen dissolved at bottling and transmitted through closures on the composition and sensory properties of a Sauvignon Blanc wine during bottle storage.](#)
*This work outlines the results from an investigation to determine the...*6th November, 2009
UMR1219 Oenologie, Faculte d'Oenologie-ISVV, 210 chemin de Leysotte, CS- J Agric Food Chem.
2009 Nov 11;57(21):10261-70. ([DOI Direct Link](#))
- [Asymptomatic Hypertension in the Emergency Department: A Matter of Critical Public Health Importance.](#)
*Abstract Asymptomatic hypertension (HTN) is commonly encountered in the...*23rd October, 2009
From the Department of Emergency Medicine, Wayne State University (PDL),- Acad Emerg Med. 2009 Oct 20. ([DOI Direct Link](#))
- [Dissociation of efficacy and cytokine release mediated by an Fc-modified anti-CD3 mAb in a chronic experimental autoimmune encephalomyelitis model.](#)
*Humanization and modification of the Fc region of anti-human CD3 mAbs have...*1st August, 2009
PDL BioPharma 1400 Seaport Blvd Redwood City, CA 94063, USA.- J Neuroimmunol. 2009 Jul 25;212(1-2):65-73. Epub 2009 May 23. ([DOI Direct Link](#))
- [Functional characterization of N297A, a murine surrogate for low-Fc binding anti-human CD3 antibodies.](#)
*Several low- or non-FcR binding anti-human CD3 monoclonal antibodies have...*26th February, 2009
Research Department, PDL BioPharma, Redwood City, California 94063, USA.- Immunol Invest. 2009;38(1):76-92. ([DOI Direct Link](#))
- [\[Systematic quality analysis of treatment outcomes based on an example of a psychiatric department: it is important what is achieved, not what is done!\]](#)

- Several low- or non-FcR binding anti-human CD3 monoclonal antibodies have...*13th January, 2009
Klinikum der Johannes-Gutenberg-Universitat- Pflege Z. 2008 Nov;61(11):620-3.
- [NS0 cell damage by high gas velocity sparging in protein-free and cholesterol-free cultures.](#)
*Recent developments in high cell density and high productivity fed-batch...*19th November, 2008
Process Sciences and Engineering, PDL BioPharma, Inc., 1400 Seaport Blvd,- Biotechnol Bioeng. 2008 Nov 1;101(4):751-60. ([DOI Direct Link](#))
 - [Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits.](#)
*Angiogenesis, the process by which new blood vessels form from existing...*10th June, 2008
PDL Biopharma, Inc., 34801 Campus Drive, Fremont, CA 94555, USA.- Invest New Drugs. 2008 Feb;26(1):7-12. Epub 2007 Sep 1. ([DOI Direct Link](#))
 - [A function blocking anti-mouse integrin alpha5beta1 antibody inhibits angiogenesis and impedes tumor growth in vivo.](#)
*BACKGROUND: Integrins are important adhesion molecules that regulate tumor...*29th March, 2008
Department of Research, PDL Biopharma, Inc., Fremont, CA 94555, USA.- J Transl Med. 2007 Nov 27;5:61. ([DOI Direct Link](#))
 - [Whole IgG surface display on mammalian cells: Application to isolation of neutralizing chicken monoclonal anti-IL-12 antibodies.](#)
*We have developed a mammalian cell surface display vector, suitable for...*8th December, 2007
PDL BioPharma, Inc., 34801 Campus Drive, Fremont, CA 94555, USA.- J Immunol Methods. 2007 Oct 31;327(1-2):40-52. Epub 2007 Aug 2. ([DOI Direct Link](#))
 - [A semi-empirical mathematical model useful for describing the relationship between carbon dioxide, pH, lactate and base in a bicarbonate-buffered cell-culture process.](#)
*The purpose of the present study was to develop a quantitative...*22nd August, 2007
Protein Design Labs, Inc., Brooklyn Park, MN 55445, USA.- Biotechnol Appl Biochem. 2007 Aug;47(Pt 4):197-204. ([DOI Direct Link](#))
 - [Main routes of oxygen ingress through different closures into wine bottles.](#)
*The main routes of oxygen ingress into wine bottles through "technical"...*19th August, 2007
Faculte d'Oenologie de Bordeaux, Universite Victor Segalen Bordeaux 2, UMR- J Agric Food Chem. 2007 Jun 27;55(13):5167-70. Epub 2007 Jun 2. ([DOI Direct Link](#))
 - [Validated alternatives: is immediate implementation required? Baluride: don't get taken for a ride.](#)
*The main routes of oxygen ingress into wine bottles through "technical"...*25th July, 2007
PDL BioPharma, Fremont, CA, USA.- Lab Anim (NY). 2007 May;36(5):13. ([DOI Direct Link](#))
 - [Cell based assays in drug development for biopharmaceuticals--IIR's Second Annual Conference.](#)
*The purpose of the present study was to develop a quantitative...*9th February, 2007
PDL Biopharma Inc, 34801 Campus Drive, Fremont, CA 94555, USA.- IDrugs. 2006 Dec;9(12):841-5.
 - [Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent.](#)
*Integrin alpha5beta1, the principal fibronectin receptor, is an important...*3rd February, 2007
PDL Biopharma- J Exp Ther Oncol. 2006;5(4):273-86.
 - [Impact of storage position on oxygen ingress through different closures into wine bottles.](#)
*Wine bottle aging is extremely dependent on the oxygen barrier properties...*21st October, 2006
Faculte d'Oenologie de Bordeaux, Universite Victor Segalen Bordeaux 2 UMR- J Agric Food Chem. 2006 Sep 6;54(18):6741-6. ([DOI Direct Link](#))

Press Releases on PDL:

[Reportlinker Adds Cell/Tissue Culture Supplies - A Global Market Perspective](#)

25th November, 2009 Reportlinker

NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cell/Tissue Culture Supplies - A Global Market Perspective <http://www>

[PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend](#)

23rd November, 2009 PDL BioPharma, Inc.

INCLINE VILLAGE, Nev., Nov. 23 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that NASDAQ has established November 27, 2009 as the ex-dividend date for its \$200

[PDL BioPharma Announces Special Dividend Payment](#)

12th November, 2009 PDL BioPharma, Inc.

INCLINE VILLAGE, Nev., Nov. 12 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it will pay a \$200 million special dividend to stockholders, with part of the

[Milestone Scientific to Exhibit at the 15th Anniversary of TBSE \(The Best Seminar Ever\) in Las Vegas](#)

9th November, 2009 Milestone Scientific Inc.

PISCATAWAY, N.J., Nov. 9 /PRNewswire-FirstCall/ -- Milestone Scientific Inc. (OTC Bulletin Board: MLSS), the recognized leader in computer-controlled injection technologies, today announced that it

[Reportlinker Adds Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight](#)

5th November, 2009 Reportlinker

NEW YORK, Nov. 5 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline

BioNews Results for PDL



- [PDL BioPharma Announces Special Dividend Payment](#)
Freshnews.com: Nov 13 2009 12:29AM Matching: pdl
- [PDL BioPharma Announces Special Dividend Payment](#)
PDL BioPharma: Nov 13 2009 1:21AM Matching: pdl
- [PDL BioPharma Announces Special Dividend Payment](#)
Red Orbit: Nov 13 2009 1:26AM Matching: pdl

- [PDL BioPharma Announces Special Dividend Payment](#)
Red Orbit: Nov 13 2009 1:26AM Matching: pdl
- [PDL BioPharma Announces Special Dividend Payment](#)
Red Orbit: Nov 13 2009 1:26AM Matching: pdl
- [PDL BioPharma Announces Special Dividend Payment](#)
Red Orbit: Nov 13 2009 1:26AM Matching: pdl
- [PDL BioPharma Announces Special Dividend Payment](#)
Red Orbit: Nov 13 2009 1:26AM Matching: pdl
- [PDL BioPharma Announces Special Dividend Payment](#)
Red Orbit: Nov 13 2009 1:24AM Matching: pdl
- [PDL BioPharma to pay \\$200 million special dividend payment to stockholders](#)
News-Medical.Net: Nov 13 2009 12:32PM Matching: pdl
- [PDL BioPharma Inc sets special dividend date for 15 December](#)
M2: Nov 13 2009 11:41AM Matching: pdl
- [Bauposts Seth Klarman Buys Enzon Inc., Viasat Inc., Sells Horizon Lines Inc., News Corp., PDL Biopharma Inc](#)
Guru Focus: Nov 13 2009 4:55AM Matching: pdl
- [PDL BioPharma Announces Special Dividend Payment](#)
Pacific Business News: Nov 12 2009 10:53PM Matching: pdl
- [PDL BioPharma Announces Special Dividend Payment / Record Date of December 1 and Payment Date of December 15 Set](#)
FinanzNachrichten.de: Nov 12 2009 10:01PM Matching: pdl
- [PDL BioPharma Announces Special Dividend Payment Record Date of December 1 and Payment Date of December 15 Set](#)
Yahoo! Canada: Nov 12 2009 11:04PM Matching: pdl
- [PDL BioPharma Announces Special Dividend Payment](#)
Baltimore Business Journal: Nov 12 2009 10:52PM Matching: pdl

PDL Clinical Trials:



- [An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative Colitis](#)

PDL Patents:



- 7435589- [Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer](#)

- 7189507- [Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer](#)
- 7183390- [Humanized antibodies to gamma-interferon](#)
- 7122185- [Anti-CCR5 antibody](#)
- 6007377- [In Line rewirable switch device](#)
- 5517165- [Switch mechanism](#)
- 5457444- [Switching mechanism](#)
- 5277512- [Joint for detachable connection of structural members](#)
- 4742927- [Tamper proof seal for a container closure](#)
- 7217797- [Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis](#)
- 7217798- [Alteration of Fc-fusion protein serum half-lives by mutagenesis](#)
- 7223393- [Amphiregulin antibodies and their use to treat cancer and psoriasis](#)
- 7399469- [Anti-LFL2 antibodies for the diagnosis, prognosis and treatment of cancer](#)
- 7381803- [Humanized antibodies against CD3](#)
- 7365168- [Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis](#)
- 7361740- [Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis](#)
- 7288248- [Antibodies against cancer antigen TMEFF2 and uses thereof](#)
- 7285268- [Chimeric and humanized antibodies to .alpha.5.beta.1 integrin that modulate angiogenesis](#)
- 7276589- [Chimeric and humanized antibodies to .alpha.5.beta.1 integrin that modulate angiogenesis](#)
- 7276372- [Antibodies against GPR64 and uses thereof](#)
- 4500008- [Weatherproof and/or dust proof fitting](#)

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical

practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

